Hyacinthe Johnson‐Ansah

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Delphine Réa, Franck E. Nicolini, Michel Tulliez et al. · Blood · 2016 · 314 citations · Full text

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck E. Nicolini, Stéphanie Dulucq, Lisa Boureau et al. · Clinical Cancer Research · 2019 · 108 citations · Full text

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Delphine Réa, Shanti Amé, Marc Berger et al. · Cancer · 2018 · 72 citations · Full text

First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia

Delphine Réa, Gabriel Étienne, Franck E. Nicolini et al. · Leukemia · 2012 · 44 citations

Hematological Malignancy, Medicine, Hematology +7

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

Philippe Rousselot, Hyacinthe Johnson‐Ansah, Françoise Huguet et al. · Blood · 2015 · 33 citations